Skip to content

Efficacy of Denosumab versus Alendronate for Aromatase Inhibitor-Associated Osteoporosis in Postmenopausal Breast Cancer Patients A Retrospective Analysis

Efficacy of Denosumab versus Alendronate for Aromatase Inhibitor-Associated Osteoporosis in Postmenopausal Breast Cancer Patients A Retrospective Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108282
Enrollment
Unknown
Registered
2025-08-27
Start date
2025-04-28
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Control group:None
Study group:None

Sponsors

Foshan hospiital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Postoperative pathology confirmed as breast cancer, immunohistochemistry confirmed hormone receptor positive; 2. Postoperative pathological stage is stage I., II., III.a; 3. Age <=75 years old, normal liver and kidney function; 4. Surgery and/or adjuvant chemotherapy and/or radiotherapy have been completed; 5. Patients treated with aromatase inhibitors after surgery; 6. Naturally postmenopausal or have undergone surgical OFS drug castration; 7. Complete clinical pathology and follow-up data, and informed consent of the patient.

Exclusion criteria

Exclusion criteria: 1. Patients with advanced breast cancer with distant metastasis; 2. Long-term glucocorticoid therapy; 3. Liver and kidney insufficiency; 4. Other diseases affecting bone metabolism; 5. Patients who have recently undergone dental surgery.

Design outcomes

Primary

MeasureTime frame
ß-C-terminal telopeptide of type-?collagen;25-hydroxy vitamin D3;procollagen type 1 N-terminal propeptide;bone mineral density;

Secondary

MeasureTime frame
visual analogue scale;vertebral compression fracture;

Countries

China

Contacts

Public ContactHou Lei

Foshan hospiital of Traditional Chinese Medicine

1940233878@qq.com+86 18566865600

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026